4-(methylthio)-3-oxobutanoic acid methyl ester | 64127-51-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 4-(methylthio)-3-oxobutanoic acid methyl ester
• 英文别名: 4-methylsulfanyl-3-oxo-butyric acid methyl ester；γ-Methylmercaptoacetessigsaeuremethylester；Methyl 4-(methylsulfanyl)-3-oxobutanoate；methyl 4-methylsulfanyl-3-oxobutanoate
• CAS: 64127-51-1
• 化学式: C₆H₁₀O₃S
• 分子量: 162.21
• InChiKey: IGIVMGGDGYMYIQ-UHFFFAOYSA-N

物化性质

• 沸点：
  212.0±20.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  68.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(methylthio)-3-oxobutanoic acid methyl ester 在 palladium on activated charcoal 盐酸 、 oil scarlet 、 氢气 、 2,4,6-三甲基苯磺酰羟胺 、 potassium carbonate 、 臭氧 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， -78.0~60.0 ℃ 、101.33 kPa 条件下， 反应 38.0h， 生成 *,R^*)>-2-hydroxy-2-<(S-methylsulfonimidoyl)methyl>butanedioic acid
  参考文献：
  名称：

  ATP-citrate-lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-.beta.-lactam containing analogs of citric acid as potential tight-binding inhibitors

  摘要：

  Citric acid analogues (+/-)-12a,b and (+/-)-17a,b, where one of the primary carboxylates has been replaced by a sulfoximinoyl and a 3-(3-hydroxy-beta-lactamyl) moiety, respectively, have been synthesized and evaluated as inhibitors of ATP-citrate lyase. The design of these inhibitors was based on methionine sulfoximine and tabtoxinine beta-lactam, potent, tight-binding inhibitors of glutamine synthetase. Both ATP-citrate lyase and glutamine synthetase employ phosphate-carboxylate anhydrides as a method for carboxylate activation during catalysis. Only one diastereomer, (+/-)-12a, displayed weak, reversible inhibition, while the remaining citrate analogues (+/-)-12b and (+/-)-17a,b were inactive against the lyase. No time-dependent inactivation of the enzyme was observed.

  DOI：

  10.1021/jm00104a014
• 作为产物：
  描述：

  甲硫醇 、 4-氯乙酰乙酸甲酯 在 sodium hydride 作用下， 生成 4-(methylthio)-3-oxobutanoic acid methyl ester
  参考文献：
  名称：

  ATP-citrate-lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-.beta.-lactam containing analogs of citric acid as potential tight-binding inhibitors

  摘要：

  Citric acid analogues (+/-)-12a,b and (+/-)-17a,b, where one of the primary carboxylates has been replaced by a sulfoximinoyl and a 3-(3-hydroxy-beta-lactamyl) moiety, respectively, have been synthesized and evaluated as inhibitors of ATP-citrate lyase. The design of these inhibitors was based on methionine sulfoximine and tabtoxinine beta-lactam, potent, tight-binding inhibitors of glutamine synthetase. Both ATP-citrate lyase and glutamine synthetase employ phosphate-carboxylate anhydrides as a method for carboxylate activation during catalysis. Only one diastereomer, (+/-)-12a, displayed weak, reversible inhibition, while the remaining citrate analogues (+/-)-12b and (+/-)-17a,b were inactive against the lyase. No time-dependent inactivation of the enzyme was observed.

  DOI：

  10.1021/jm00104a014

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备目前发明的化合物的新工艺和中间体。还发明了一种治疗血小板减少症的方法，包括给予需要的哺乳动物，包括人类，有效量的选择性羟基-1-偶氮苯衍生物。
• Substituted indoles as alpha-1 agonists
  申请人：——

  公开号：US20030220319A1

  公开（公告）日：2003-11-27

  This invention relates to compounds which are alpha-1 receptor agonists, preferably alpha-1A/L receptor agonists, and which are represented by Formula I: 1 wherein X is —S(O) n — or —C(O)—, A is C 1-6 alkyl, aryl, heteroaryl, hydroxyalkyl, or —(CH 2 ) p —NR a R b , and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

  这项发明涉及α-1受体激动剂，优选为α-1A/L受体激动剂，其化学式如下：其中X为—S(O)n—或—C(O)—，A为C1-6烷基，芳基，杂环芳基，羟基烷基，或—(CH2)p—NRaRb，其他取代基如规范中所定义；或其各个异构体，消旋体或非消旋体混合物，或其药用盐或溶剂化合物。该发明还涉及含有这类化合物的药物组合物，以及它们作为治疗剂的使用方法和制备方法。
• Substituted triazolopyrimidines and their use in light-sensitive photographic elements
  申请人：AGFA-GEVAERT naamloze vennootschap

  公开号：EP0190375A1

  公开（公告）日：1986-08-13

  Photographic element comprising a support and a silver halide emulsion layer comprising in said emulsion layer and/or in a water-permeable layer coated at the same side of the support as said emulsion layer a compound corresponding to the following general formula: wnerein: each of R1, R2, and R3, which may be the same or diffc can represent hydrogen, C1-C8alkyl, or Alk, - X - Alk2-. wherein: Alk, is C1-C8alkyl, which may be substituted, X is -0- or -S- , Alk2 is C1-C8alkylene, which may be substituted, and Y is a single bond, -0-, -S- , -CONH- , -SO2NH- , or -NHCONH-, R3 can alternatively represent C1-C8alkyl-thio, the C1-C8alkyl group of which can be substituted, at least one of R1, R2, and R3, however, being other than hydrogen and other than C1-C8alkyl. The invention disclosed includes compounds per se, which correspond to said general formula.

  摄影元件，包括一个支架和一个卤化银乳剂层，在所述乳剂层中和/或在与所述乳剂层位于支架同一侧的透水层中涂覆有与下式通式相对应的化合物： 其中，R1、R2 和 R3 可以相同或不同地代表氢、C1-C8 烷基或 Alk、- X - Alk2-： X为-0-或-S-，Alk2为C1-C8亚烷基，可被取代，Y为单键、-0-、-S-、-CONH-、-SO2NH-或-NHCONH-、 R3 也可以代表 C1-C8 烷硫基，其中的 C1-C8 烷基可以被取代。 基团可以被取代、 但 R1、R2 和 R3 中至少有一个不是 氢和 C1-C8 烷基以外。 所公开的本发明包括符合所述通式的化合物本身。
• DE2726464
  申请人：——

  公开号：——

  公开（公告）日：——
• Dolle Roland E., McNair David, Hughes Mark J., Kruse Lawrence I., Eggelst+, J. Med. Chem., 35 (1992) N 26, S 4875-4884
  作者：Dolle Roland E., McNair David, Hughes Mark J., Kruse Lawrence I., Eggelst+

  DOI：——

  日期：——